Aristo Bio-Tech and Lifescience logo

Aristo Bio-Tech and Lifescience financials and balance sheet

NSE: ARISTOFertilizers & Agrochemicals

Last close ₹86.00down ₹2.20 (2.49%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹88.20.

52-week range of traded prices to 23 Oct 2026
₹74.30Low, 2 Apr 2026₹135.00High, 23 Oct 2025
Market cap
₹59 Cr
P/E
8.2
P/B
1.3
Dividend yield
0.70%
ROE
17.6%
Debt to equity
0.80
Volume, NSE
2,400100.0% delivered

4 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Aristo Bio-Tech and Lifescience annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹364 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue364
  2. Materials and goods−331
  3. Employee costs−5.0
  4. Other expenses−12
  5. Operating profit16
  6. Depreciation−2.9
  7. Other income+0.5
  8. Finance costs−3.9
  9. Profit before tax9.7
  10. Tax−2.5
  11. Net profit7.2

What the company owns

  • Inventory₹63 Cr
  • Receivables₹55 Cr
  • Plant, investments and other assets₹35 Cr
  • Cash and bank₹3 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹71 Cr
  • Net worth₹45 Cr
  • Borrowings₹35 Cr
  • Other liabilities₹4 Cr

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the year to Mar 2024.Aristo Bio-Tech and Lifescience half-yearly results

₹ croreMar 2023Mar 2024Mar 2025Filed 29 MayMar 2026Filed 30 May
Revenue from operations218–318364
209–309348
Materials and goods bought196–296331
Employee costs6–45
Other expenses8–912
Operating profit before depreciation9–916
Operating margin4.0%–2.9%4.4%
Materials, % of revenue89.9%–92.9%90.9%
Employee costs, % of revenue2.6%–1.3%1.4%
Other expenses, % of revenue3.5%–2.9%3.3%
Depreciation and amortisation2–33
Operating profit after depreciation7–713
Other income0–00
Finance costs3–24
One-off items0–––
Profit before tax5–510
1–13
Net profit4–47
Net margin1.6%–1.3%2.0%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2025Filed 29 MayMar 2026Filed 30 May
3745
Share capital77
Reserves3138
2235
96103
88
Total assets141155
2525
116130
Net debt2133
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2023, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2025Filed 29 MayMar 2026Filed 30 May
10.08.4
11.511.1
1.8−5.4
Receivables1.31.5
Inventories−7.2−15.8
Payables8.9−7.6
Other working capital−1.316.5
Tax paid0.0−2.5
Capital spending5.12.6
Free cash flow4.95.8
−5.1−3.0
−4.4−4.0
Dividends paid0.3–
Shares issued0.00.0
Net change in cash0.51.5
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2023. Dividends paid is left blank for the year to Mar 2026: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given.

Per share

Standalone, ₹ per share, years to March.Aristo Bio-Tech and Lifescience dividend history

₹ per shareMar 2023Mar 2024Mar 2025Filed 29 MayMar 2026Filed 30 May
Earnings per share––₹5.97₹10.55
Diluted earnings per share––₹5.97₹10.55
Dividend per share₹0.25–₹0.50₹0.60
Book value per share––₹54.84₹65.39
Dividend payout4.8%–8.4%5.7%
Shareholder yield––0.4%–
Market cap at the year end (₹ crore)38.2–79.151.1
Shareholder yield is left blank for the year to Mar 2026: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given.
RatioMar 2023Mar 2024Mar 2025Filed 29 MayMar 2026Filed 30 May
Revenue growth–––14.3%
Operating profit growth–––73.1%
Net profit growth–––76.8%
Earnings per share growth–––76.7%
––10.9%17.6%
–––6.7 pts
From the net margin–––5.9 pts
From asset turnover–––1.5 pts
From borrowing–––−0.7 pts
Return on capital employed––11.3%16.4%
Cash conversion––246.5%117.6%
Interest cover2.6–4.03.4
Debt to equity––0.590.80
Receivable days––6455
Inventory days––5870
Payable days––9778
Cash conversion cycle, days––2646
Working capital days––3852
Asset turnover––2.262.46
Assets per rupee of net worth––3.773.61
Sales per rupee of plant––13.2815.39
Capital spending to depreciation––1.960.89
No balance sheet is on record for the year to Mar 2023, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.9%
Cash from operations against operating profit
52.6%
Measure3 years
Revenue growth, yearly rate18.6%
Profit growth, yearly rate26.3%
Return on equity, average14.2%
Return on capital employed, average13.8%
Operating margin, average3.7%
Net margin, average1.6%
Asset turnover, average2.36
Cash conversion cycle, days, average36
Interest cover, average3.7
Debt to equity, average0.69

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations8.44
Cash from investing−2.97
Cash from financing−3.96
Capital spending2.61
Shares issued for cash0.00
Borrowings raised0.00
Borrowings repaid0.08

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–––−16.94
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––21.53
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−0.41
Effective tax ratePublished threshold 17.16 per cent24.83–25.6825.93
Tax charged less tax paid, % of profitOur threshold 10 percentage points––25.000.00
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
6 Oct 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesShort-term scaleCrisil A4(Issuer Not Cooperating)Rating Revised1
6 Oct 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil B(Issuer Not Cooperating)Rating RevisedStable9
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.